# SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma

> **NCT04930315** · PHASE2 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 78 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Apatinib Mesylate
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04930315
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-15
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04930315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04930315, "SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04930315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*